{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:21:30Z","timestamp":1793575290271,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1093\/rheumatology\/key213","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T11:16:14Z","timestamp":1530011774000},"page":"2106-2113","source":"Crossref","is-referenced-by-count":233,"title":["Intravenous cyclophosphamide<i>vs<\/i>rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial"],"prefix":"10.1093","volume":"57","author":[{"given":"Geetabali","family":"Sircar","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudra Prosad","family":"Goswami","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipankar","family":"Sircar","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Institute of Postgraduate Medical Education and Research, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alakendu","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parasar","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,26]]},"reference":[{"key":"key\n\t\t\t\t2018112705033308100_key213-B1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B2","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B3","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B4","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.09-0108","article-title":"Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study","volume":"136","author":"Goldin","year":"2009","journal-title":"Chest"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B6","first-page":"w14030","article-title":"Cyclophosphamide: as bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases","volume":"144","author":"Dan","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2217\/imt.10.69","article-title":"Immunotherapy of systemic sclerosis","volume":"2","author":"Manno","year":"2010","journal-title":"Immunotherapy"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdermsci.2006.12.004","article-title":"B cell signaling and autoimmune diseases: cD19\/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity","volume":"46","author":"Fujimoto","year":"2007","journal-title":"J Dermatol Sci"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B9","doi-asserted-by":"crossref","first-page":"12319","DOI":"10.1073\/pnas.1635114100","article-title":"Systemic and cell type-specific gene expression patterns in scleroderma skin","volume":"100","author":"Whitfield","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B10","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B11","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.rbr.2016.04.001","article-title":"Tratamento da esclerose sist\u00eamica com rituximabe: uma s\u00e9rie de 10 casos em centro \u00fanico","volume":"56","author":"Vilela","year":"2016","journal-title":"Rev Bras Reumatol"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1753465811407786","article-title":"Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids","volume":"5","author":"Haroon","year":"2011","journal-title":"Ther Adv Respir Dis"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B14","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00296-012-2587-x","article-title":"Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience","volume":"33","author":"Braun-Moscovici","year":"2013","journal-title":"Rheumatol Int"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/03009742.2015.1069888","article-title":"Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: a promising surveillance marker of therapy?","volume":"44","author":"Moazedi-Fuerst","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B17","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B19","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B20","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI0215078","article-title":"CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse","volume":"109","author":"Saito","year":"2002","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B21","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.4049\/jimmunol.167.10.5669","article-title":"Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state","volume":"167","author":"Bar-Or","year":"2001","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B23","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1186\/ar3879","article-title":"B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin","volume":"14","author":"Daoussis","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B25","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"key":"key\n\t\t\t\t2018112705033308100_key213-B27","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/57\/12\/2106\/26769440\/key213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T00:22:23Z","timestamp":1571530943000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/57\/12\/2106\/5060036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,7,26]]},"published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key213","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,7,26]]}}}